HRT Financial’s Nektar Therapeutics NKTR Stock Holding History

HRT Financial’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,400	Closed	-$705K	–	3745
2025 Q3	$705K	Buy	+12,400	New	+$410K	﹤0.01%	1697

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's NKTR Position: Q2 2026 in Review

HRT Financial sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 70,667 shares — an estimated $5.17M sold.

HRT Financial first reported a position in NKTR in Q2 2018 and held it in 20 quarters. The position peaked at $7.33M in Q4 2025. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

HRT Financial reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 70,667 Nektar Therapeutics shares in Q2 2026, an estimated $5.17M.
HRT Financial first reported a position in Nektar Therapeutics in Q2 2018 and held it in 20 quarters.
HRT Financial's Nektar Therapeutics position peaked at $7.33M in Q4 2025.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.